Breast Cancer
Conference Coverage
Dr. William J. Gradishar shares breast cancer take-aways from ASCO 2018
CHICAGO – TAILORx is a “big win,” while SANDPIPER results are nothing to get excited about.
Conference Coverage
PI3K inhibitor/fulvestrant has modest benefit, serious toxicity in breast cancer
CHICAGO – The combination of talesib/fulvestrant extended PFS by two months, but at a cost of serious toxicities in half of the patients treated...
Video
TAILORx: Most women with intermediate risk ER+ breast cancer can safely skip chemo
CHICAGO - Lead study author Dr. Joseph A. Sparano discusses the implications of the new data for decision-making and future plans for the tumor...
Clinical Review
Who needs breast cancer genetics testing?
Identifying patients who are appropriate candidates for breast cancer genetics testing is a key step toward prevention and value-based care
Expert Commentary
Should breast cancer screening guidelines be tailored to a patient’s race and ethnicity?
Yes. Because women of minor ity races/ethnicities have an earlier age of onset of breast cancer (45 to 50 years) compared with...
From the Journals
Ketorolac may reduce breast cancer recurrence risk, particularly in overweight patients
Investigators found a significant association between interoperative ketorolac and decreased incidence of distant metastasis, with reduced...
Gynecologic Oncology Consult
Oophorectomy for premenopausal breast cancer
In this month’s Gynecologic Oncology Consult, Dr. Emma Rossi discusses ovarian ablation and removal in treatment of breast cancer.
Conference Coverage
Adjuvant trastuzumab for breast cancer: 6 months may suffice
Disease-free survival was similarly high whether women received adjuvant trastuzumab for the current standard of 12 months or for just 6 months....
From the Journals
Breast cancer: More pathogenic variants detected as multiple-gene sequencing takes over
Multiple-gene sequencing has rapidly replaced BRCA1/2-only testing in community practice.
Conference Coverage
Universal BRCA testing worthwhile for relatives of high-grade serous ovarian cancer patients
AUSTIN, TEX. – BRCA testing could add more than a decade of life to women at risk for ovarian cancer.
Conference Coverage
VIDEO: Office-based hereditary cancer risk testing is doable
AUSTIN, TEXAS - Few community-based ob.gyns. routinely screen their patients for hereditary cancer risks, despite ACOG's position that they are...